Kidney Cancer
Feb 9, 2025, 15:06
ctDNA: A game-changer in kidney cancer?
María Natalia Gandur Quiroga, Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute, shared an article by Alan Tan, et al. on X:
“ctDNA: A game-changer in kidney cancer?
New study published!
Author: Alan Tan
Title: Exploring the potential role of ctDNA as a biomarker in kidney cancer.
Date: February 7, 2025
Key takeaways:
ctDNA shows high concordance with disease progression in metastatic RCC.
Prognostic value:
- MRD positivity linked to progression, while ctDNA negativity suggests indolent disease.
- Could help monitor treatment response & recurrence risk.
- Ongoing trials aim to refine its role in de-escalating therapy.
This could reshape RCC management, offering precision monitoring & personalized therapy.”
Exploring the potential role of ctDNA as a biomarker in kidney cancer.
Author: Alan Tan
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 18:57
Apr 15, 2025, 18:26
Apr 15, 2025, 17:49
Apr 15, 2025, 17:41